In the present study, we demonstrated that JMF3086, a dual inhibitor targeting HMGR and HDAC, significantly improved neurite degeneration in LRRK2-G2019S parkinsonism models both in vivo and in vitro. Here, HDAC9 is linked to Parkinson disease.